FDA's Anesthetic & Life Support Drugs Advisory Committee will discuss the benefits and risks of the medical use of opiate analgesics in pediatric patients and patients with chronic pain of nonmalignant etiology Sept. 13 and 14. The committee will also address concerns regarding abuse potential, diversion and increase of addiction to modified release opiate analgesics. Purdue Pharma has developed an education program to prevent abuse of its controlled-release oxycodone product OxyContin. The meeting will begin at 8 a.m. both days at the University of Maryland-Shady Grove. An advisory committee meeting on the topics had been scheduled for June 14-15
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth